Literature DB >> 21066977

Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2).

V Valentini1, C Coco, M A Gambacorta, M C Barba, E Meldolesi.   

Abstract

PURPOSE: Although surgery remains the most important treatment of rectal cancer, the management of this disease has evolved to become more multidisciplinary to offer the best clinical outcome. The International Conference on Multidisciplinary Rectal Cancer Treatment: Looking for an European Consensus' (EURECA-CC2) had the duty to identify the degree of consensus that could be achieved across a wide range of topics relating to the management of rectal cancer helping shape future programs, investigational protocols and guidelines for staging and treatment throughout Europe.
MATERIALS AND METHODS: Consensus was achieved using the Delphi method. Eight chapters were identified: epidemiology, diagnostics, pathology, surgery, radiotherapy and chemotherapy, treatment toxicity and quality of life, follow-up, and research questions. Each chapter was subdivided by topic, and a series of statements were developed. Each committee member commented and voted, sentence by sentence three times. Sentences which did not reach agreement after voting round #2 were openly debated during the Conference in Perugia (Italy) December 2008. The Executive Committee scored percentage consensus based on three categories: "large consensus", "moderate consensus", "minimum consensus".
RESULTS: The total number of the voted sentences was 207. Of the 207, 86% achieved large consensus, 13% achieved moderate consensus, and only 3 (1%) resulted in minimum consensus. No statement was disagreed by more than 50% of members. All chapters were voted on by at least 75% of the members, and the majority was voted on by 85%.
CONCLUSIONS: This Consensus Conference represents an expertise opinion process that may help shape future programs, investigational protocols, and guidelines for staging and treatment of rectal cancer throughout Europe. In spite of substantial progress, many research challenges remain.

Entities:  

Mesh:

Year:  2010        PMID: 21066977     DOI: 10.2298/aci1003009v

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  6 in total

Review 1.  [Frozen sections diagnostics in visceral surgery. Stomach and intestines].

Authors:  B Oberschmid; A Dietrich; C Wittekind
Journal:  Pathologe       Date:  2012-09       Impact factor: 1.011

2.  Performance of gadofosveset-enhanced MRI for staging rectal cancer nodes: can the initial promising results be reproduced?

Authors:  Luc A Heijnen; Doenja M J Lambregts; Milou H Martens; Monique Maas; Frans C H Bakers; Vincent C Cappendijk; Pedro Oliveira; Guido Lammering; Robert G Riedl; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2013-09-20       Impact factor: 5.315

3.  Neoadjuvant radiotherapy for rectal cancer: adherence to evidence-based guidelines in clinical practice.

Authors:  Timothy L Fitzgerald; Tithe Biswas; Kevin O'Brien; Emmanuel E Zervos; Jan H Wong
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

4.  Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.

Authors:  Atil Bisgin; Aysegul Kargi; Arzu D Yalcin; Cigdem Aydin; Deniz Ekinci; Burhan Savas; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2012-02-07       Impact factor: 4.430

5.  Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.

Authors:  Jessica Wagner; C Leah Kline; Lanlan Zhou; Vladimir Khazak; Wafik S El-Deiry
Journal:  J Exp Clin Cancer Res       Date:  2018-01-22

6.  Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.

Authors:  Betül Celik; Arzu Didem Yalcin; Atil Bisgin; Antonia Dimitrakopoulou-Strauss; Aysegül Kargi; Ludwig G Strauss
Journal:  Med Sci Monit       Date:  2013-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.